PLANTATION, Fla., March 23 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to present at
Biotech 2004, hosted by Florida International University at their Graham
University Center in Miami on Thursday, March 25. Biotech 2004 promotes
collaboration among leading bioscience firms and university researchers within
South Florida.
Event: Biotech 2004, "Today's Bioscience Environment in South Florida"
When: 9:00 a.m. - 5:30 p.m. (EST), March 25, 2004
Where: FIU's Graham University Center on the Miami Campus
Fee: Corporate $100; University Personnel $30; and Students $15
To RSVP or obtain the program's agenda: Contact Chris Kennelly, Director
of Programs for Enterprise Development Corporation at ckennelly@edc-tech.org
Or visit: http://www.edc-tech.org
In other news, Viragen announced that a summary of its Annual Meeting of
Stockholders, held on March 12, is available on the Company's website and can
also be obtained by contacting the Company and requesting a copy.
For more information, please visit: http://www.Viragen.com
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies, peptide drugs and therapeutic vaccines. Viragen's strategy also
includes the development of Avian Transgenic Technology for the large-scale,
cost-effective manufacturing of its portfolio of protein-based drugs, as well
as offering Contract Manufacturing for the biopharmaceutical industry.
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com
The foregoing press release contains forward-looking statements that can
be identified by such terminology such as "expect", "potential", "suggests",
"may", "will", "should", "could" or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results to be materially different from any future
results, performance or achievements expressed or implied by such statements.
In particular, management's expectations regarding future research,
development and/or commercial results could be affected by, among other
things, uncertainties relating to clinical trials and product development;
availability of future financing; unexpected regulatory delays or government
regulation generally; the Company's ability to obtain or maintain patent and
other proprietary intellectual property protection; and competition in
general. Forward-looking statements speak only as to the date they are made.
The Company does not undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, +1-954-233-8746, or fax, +1-954-233-1414, or e-mail,
dcalder@viragen.com
|
